Response Biomedical Corp.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2013 | $3 M | No. 4 | $2 to $10 million | equity, options | SEC | |
| Dec 2011 | $5 M | No. 3 | $2 to $10 million | equity, options | SEC | |
| Jul 2010 | $8 M | No. 2 | $2 to $10 million | equity | SEC | |
| May 2009 | $4 M | No. 1 | $2 to $10 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Response Biomedical Corp. chose not to state its revenue in its newest notice of a funding round (Oct 2013).
SEC Form D · Oct 2013
The industry group it chose in its notices: Biotechnology.
SEC Form D · Oct 2013
That is all the official record says: Response Biomedical Corp. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Response Biomedical Corp. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 12 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Jeffrey L. Purvin | Executive officer | Oct 2013 |
| William J. Adams | Executive officer | Oct 2013 |
| Anastasios A. Tsonis | Executive officer | Jan 2012 |
| Dr. Peter A. Thompson | Executive officer | Jan 2012 |
| Duane A. Morris | Executive officer | Aug 2010 |
| Livleen A. Kaler | Executive officer | Aug 2010 |
| S. Wayne Kay | Executive officer | Aug 2010 |
| Livleen Kaler | Executive officer | May 2009 |
| Paul Harris | Executive officer | May 2009 |
| Anthony F. Holler | Director | Oct 2013 |
| Clinton H. Severson | Director | Oct 2013 |
| David A. Wang | Director | Oct 2013 |
| Jeffrey L. Purvin | Director | Oct 2013 |
| Joseph D. Keegan | Director | Oct 2013 |
| Lewis H. Shuster | Director | Oct 2013 |
| Peter A. Thompson | Director | Oct 2013 |
| Clint J. Severson | Director | Jan 2012 |
| Dr. Anthony F. Holler | Director | Jan 2012 |
| Dr. David J. Wang | Director | Jan 2012 |
| Dr. Joseph D. Keegan | Director | Jan 2012 |
| Dr. Peter A. Thompson | Director | Jan 2012 |
| Lewis J. Shuster | Director | Jan 2012 |
| Anthony A. Holler | Director | Aug 2010 |
| Jonathan A. Wang | Director | Aug 2010 |
| Richard A. Bastiani | Director | Aug 2010 |
| Richard A. Bear | Director | Aug 2010 |
| S. Wayne Kay | Director | Aug 2010 |
| Todd A. Patrick | Director | Aug 2010 |
| Ian A. Webb | Director | May 2009 |
| Richard J. Bastiani | Director | May 2009 |
| Richard K. Bear | Director | May 2009 |
| Todd R. Patrick | Director | May 2009 |